| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 42 | 2019 | 732 | 4.760 |
Why?
|
| Endothelial Cells | 38 | 2019 | 536 | 2.490 |
Why?
|
| Coronary Vessels | 34 | 2013 | 529 | 2.480 |
Why?
|
| Endothelium, Vascular | 41 | 2012 | 471 | 2.440 |
Why?
|
| GPI-Linked Proteins | 9 | 2019 | 105 | 1.900 |
Why?
|
| AIDS Vaccines | 8 | 2016 | 31 | 1.890 |
Why?
|
| Dendritic Cells | 12 | 2013 | 438 | 1.770 |
Why?
|
| Cell Proliferation | 24 | 2019 | 2463 | 1.630 |
Why?
|
| Thymosin | 9 | 2013 | 22 | 1.440 |
Why?
|
| Nitric Oxide Synthase Type III | 28 | 2019 | 187 | 1.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2013 | 1989 | 1.150 |
Why?
|
| Interleukin-6 | 6 | 2013 | 419 | 1.040 |
Why?
|
| Vasodilation | 21 | 2012 | 174 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2023 | 825 | 1.020 |
Why?
|
| Simian Immunodeficiency Virus | 6 | 2010 | 100 | 1.010 |
Why?
|
| Ritonavir | 12 | 2019 | 45 | 1.010 |
Why?
|
| Neoplasms | 16 | 2023 | 2969 | 1.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 12 | 2013 | 643 | 1.000 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 7 | 2023 | 138 | 0.940 |
Why?
|
| Virion | 5 | 2009 | 116 | 0.900 |
Why?
|
| Cell Line, Tumor | 28 | 2016 | 3673 | 0.890 |
Why?
|
| Cation Transport Proteins | 6 | 2013 | 101 | 0.870 |
Why?
|
| Superoxides | 28 | 2012 | 129 | 0.860 |
Why?
|
| Vaccines, Virus-Like Particle | 3 | 2016 | 29 | 0.850 |
Why?
|
| HIV Protease Inhibitors | 11 | 2012 | 44 | 0.810 |
Why?
|
| Lipopolysaccharide Receptors | 7 | 2010 | 53 | 0.790 |
Why?
|
| HIV Infections | 11 | 2016 | 2037 | 0.780 |
Why?
|
| MicroRNAs | 8 | 2013 | 894 | 0.770 |
Why?
|
| Animals | 103 | 2021 | 34371 | 0.740 |
Why?
|
| Receptors, Somatostatin | 7 | 2008 | 55 | 0.740 |
Why?
|
| Monocytes | 8 | 2007 | 337 | 0.720 |
Why?
|
| Oxidative Stress | 22 | 2019 | 807 | 0.710 |
Why?
|
| HIV-1 | 7 | 2016 | 477 | 0.700 |
Why?
|
| Cytokines | 13 | 2012 | 1347 | 0.680 |
Why?
|
| Cell Differentiation | 17 | 2009 | 1947 | 0.670 |
Why?
|
| Cell Adhesion Molecules | 3 | 2011 | 227 | 0.660 |
Why?
|
| Muscle, Smooth, Vascular | 13 | 2012 | 232 | 0.660 |
Why?
|
| Ginsenosides | 5 | 2019 | 16 | 0.660 |
Why?
|
| CD40 Ligand | 3 | 2010 | 65 | 0.660 |
Why?
|
| Enzyme Inhibitors | 4 | 2023 | 566 | 0.650 |
Why?
|
| Adenocarcinoma | 8 | 2021 | 1000 | 0.650 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 234 | 0.640 |
Why?
|
| Humans | 151 | 2023 | 131604 | 0.620 |
Why?
|
| RNA, Messenger | 40 | 2013 | 2567 | 0.610 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2019 | 177 | 0.610 |
Why?
|
| Down-Regulation | 19 | 2019 | 659 | 0.600 |
Why?
|
| Antigens, Neoplasm | 4 | 2011 | 405 | 0.600 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2019 | 27 | 0.600 |
Why?
|
| Signal Transduction | 14 | 2019 | 4683 | 0.590 |
Why?
|
| RNA, Small Interfering | 4 | 2011 | 665 | 0.580 |
Why?
|
| Antioxidants | 16 | 2016 | 336 | 0.580 |
Why?
|
| C-Reactive Protein | 5 | 2007 | 455 | 0.580 |
Why?
|
| Cell Movement | 12 | 2016 | 881 | 0.570 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2008 | 341 | 0.570 |
Why?
|
| Neovascularization, Pathologic | 6 | 2011 | 234 | 0.570 |
Why?
|
| Cells, Cultured | 30 | 2013 | 2971 | 0.570 |
Why?
|
| Cell Membrane Permeability | 3 | 2008 | 67 | 0.570 |
Why?
|
| Viral Vaccines | 3 | 2009 | 317 | 0.570 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 611 | 0.550 |
Why?
|
| NF-kappa B | 5 | 2013 | 449 | 0.530 |
Why?
|
| Apoptosis | 7 | 2013 | 1861 | 0.520 |
Why?
|
| Virus Inactivation | 2 | 2016 | 10 | 0.520 |
Why?
|
| Hyperuricemia | 2 | 2016 | 38 | 0.510 |
Why?
|
| Atherosclerosis | 12 | 2012 | 947 | 0.510 |
Why?
|
| Semaphorins | 1 | 2016 | 35 | 0.510 |
Why?
|
| MAP Kinase Signaling System | 7 | 2016 | 305 | 0.500 |
Why?
|
| Reactive Oxygen Species | 9 | 2019 | 518 | 0.500 |
Why?
|
| Myocytes, Smooth Muscle | 11 | 2012 | 185 | 0.490 |
Why?
|
| Mice | 37 | 2021 | 18486 | 0.490 |
Why?
|
| Membrane Glycoproteins | 3 | 2008 | 421 | 0.490 |
Why?
|
| Protein S | 2 | 2013 | 9 | 0.490 |
Why?
|
| Cyclophilins | 2 | 2006 | 19 | 0.470 |
Why?
|
| HIV | 3 | 2010 | 179 | 0.470 |
Why?
|
| Proteins | 3 | 2011 | 1027 | 0.470 |
Why?
|
| Cyclophilin A | 4 | 2011 | 14 | 0.450 |
Why?
|
| Reassortant Viruses | 2 | 2004 | 28 | 0.440 |
Why?
|
| Swine | 26 | 2012 | 1188 | 0.430 |
Why?
|
| Vaccines, Inactivated | 1 | 2015 | 149 | 0.420 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2013 | 7 | 0.420 |
Why?
|
| Thromboplastin | 1 | 2013 | 19 | 0.410 |
Why?
|
| Benzaldehydes | 1 | 2013 | 13 | 0.410 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.410 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 5 | 2010 | 85 | 0.410 |
Why?
|
| Enzyme Activation | 8 | 2013 | 589 | 0.410 |
Why?
|
| Selenium-Binding Proteins | 1 | 2013 | 2 | 0.400 |
Why?
|
| Selenium | 1 | 2013 | 15 | 0.400 |
Why?
|
| Neuropilins | 4 | 2005 | 9 | 0.400 |
Why?
|
| Mice, Nude | 11 | 2016 | 714 | 0.400 |
Why?
|
| Ginkgo biloba | 3 | 2008 | 11 | 0.400 |
Why?
|
| HIV Core Protein p24 | 1 | 2013 | 10 | 0.400 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 1810 | 0.390 |
Why?
|
| Azides | 1 | 2013 | 11 | 0.390 |
Why?
|
| Phytotherapy | 3 | 2008 | 46 | 0.390 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2013 | 33 | 0.380 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 199 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 460 | 0.380 |
Why?
|
| Gout Suppressants | 1 | 2013 | 75 | 0.380 |
Why?
|
| Cyclin E | 2 | 2010 | 32 | 0.380 |
Why?
|
| HIV Antibodies | 4 | 2016 | 69 | 0.370 |
Why?
|
| Immunoglobulin G | 4 | 2015 | 810 | 0.370 |
Why?
|
| Homocysteine | 8 | 2008 | 118 | 0.370 |
Why?
|
| Basigin | 3 | 2006 | 12 | 0.360 |
Why?
|
| Resistin | 6 | 2013 | 30 | 0.360 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 6 | 2013 | 125 | 0.360 |
Why?
|
| Immunotherapy, Active | 2 | 2011 | 18 | 0.360 |
Why?
|
| Lymphocyte Activation | 3 | 2009 | 680 | 0.360 |
Why?
|
| Lysophospholipids | 1 | 2012 | 39 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 17 | 2010 | 1236 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1356 | 0.350 |
Why?
|
| Somatostatin | 4 | 2005 | 60 | 0.350 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 40 | 0.340 |
Why?
|
| Transforming Growth Factor beta | 4 | 2011 | 463 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 173 | 0.340 |
Why?
|
| Vascular Diseases | 8 | 2010 | 155 | 0.340 |
Why?
|
| Glycoproteins | 3 | 2008 | 344 | 0.330 |
Why?
|
| Antigens, CD | 10 | 2009 | 418 | 0.330 |
Why?
|
| Autoantibodies | 1 | 2013 | 466 | 0.330 |
Why?
|
| Neuropeptides | 3 | 2006 | 111 | 0.330 |
Why?
|
| Disease Models, Animal | 13 | 2013 | 4696 | 0.320 |
Why?
|
| Cell Cycle | 4 | 2019 | 598 | 0.310 |
Why?
|
| Adjuvants, Immunologic | 4 | 2016 | 393 | 0.310 |
Why?
|
| In Vitro Techniques | 15 | 2011 | 824 | 0.310 |
Why?
|
| RNA, Neoplasm | 3 | 2009 | 127 | 0.310 |
Why?
|
| Plant Extracts | 3 | 2008 | 139 | 0.310 |
Why?
|
| Genetic Therapy | 6 | 2016 | 726 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 344 | 0.310 |
Why?
|
| Pyrimidines | 1 | 2013 | 443 | 0.300 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 191 | 0.300 |
Why?
|
| Chaperonin 60 | 1 | 2009 | 32 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2006 | 189 | 0.300 |
Why?
|
| Pulmonary Artery | 5 | 2011 | 441 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2013 | 1625 | 0.300 |
Why?
|
| SAIDS Vaccines | 1 | 2009 | 12 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 6 | 2019 | 989 | 0.290 |
Why?
|
| T-Lymphocytes | 5 | 2010 | 1788 | 0.290 |
Why?
|
| Plasma Cells | 1 | 2009 | 55 | 0.290 |
Why?
|
| Anus Neoplasms | 1 | 2009 | 43 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 482 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 53 | 0.290 |
Why?
|
| Cell Survival | 6 | 2016 | 853 | 0.280 |
Why?
|
| Superoxide Dismutase | 5 | 2019 | 179 | 0.280 |
Why?
|
| Kaempferols | 1 | 2008 | 6 | 0.280 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 9 | 0.280 |
Why?
|
| Cell Culture Techniques | 10 | 2009 | 275 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 4769 | 0.280 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 124 | 0.280 |
Why?
|
| Cell Line | 11 | 2019 | 2605 | 0.280 |
Why?
|
| Vaccination | 3 | 2013 | 1040 | 0.280 |
Why?
|
| Recombinant Proteins | 9 | 2011 | 1316 | 0.270 |
Why?
|
| Tyrosine | 5 | 2012 | 148 | 0.270 |
Why?
|
| Lymph Nodes | 2 | 2009 | 376 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2013 | 1001 | 0.270 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2006 | 62 | 0.270 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 50 | 0.270 |
Why?
|
| Gene Targeting | 1 | 2008 | 170 | 0.260 |
Why?
|
| Immunohistochemistry | 12 | 2011 | 1610 | 0.260 |
Why?
|
| Gene Expression | 13 | 2013 | 1501 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2011 | 88 | 0.260 |
Why?
|
| Carcinoma | 1 | 2009 | 283 | 0.260 |
Why?
|
| Interleukin-8 | 1 | 2008 | 207 | 0.260 |
Why?
|
| Pentoxifylline | 1 | 2007 | 20 | 0.260 |
Why?
|
| Macrophages | 6 | 2012 | 666 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 93 | 0.250 |
Why?
|
| Bradykinin | 11 | 2012 | 45 | 0.250 |
Why?
|
| Free Radical Scavengers | 4 | 2016 | 56 | 0.250 |
Why?
|
| Cardiovascular Diseases | 9 | 2014 | 2082 | 0.250 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2016 | 517 | 0.250 |
Why?
|
| RNA Interference | 5 | 2013 | 496 | 0.250 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 1005 | 0.240 |
Why?
|
| Endocytosis | 1 | 2006 | 129 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 5 | 2011 | 106 | 0.240 |
Why?
|
| Interferon-gamma | 4 | 2011 | 542 | 0.240 |
Why?
|
| Blotting, Western | 10 | 2011 | 1018 | 0.240 |
Why?
|
| Colorectal Neoplasms | 3 | 2010 | 639 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2007 | 551 | 0.230 |
Why?
|
| Cyclosporine | 1 | 2005 | 129 | 0.230 |
Why?
|
| Catechols | 2 | 2016 | 9 | 0.220 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2005 | 54 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 13 | 2009 | 168 | 0.220 |
Why?
|
| Phosphorylation | 7 | 2010 | 1571 | 0.220 |
Why?
|
| Hypochlorous Acid | 2 | 2016 | 4 | 0.210 |
Why?
|
| Nervous System | 1 | 2005 | 123 | 0.210 |
Why?
|
| Foam Cells | 3 | 2009 | 21 | 0.210 |
Why?
|
| DNA Primers | 7 | 2011 | 609 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2007 | 765 | 0.210 |
Why?
|
| Neuropilin-1 | 3 | 2010 | 14 | 0.210 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2012 | 46 | 0.200 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 21 | 0.200 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 944 | 0.200 |
Why?
|
| STAT3 Transcription Factor | 4 | 2010 | 233 | 0.200 |
Why?
|
| Polyglycolic Acid | 2 | 2016 | 20 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 759 | 0.200 |
Why?
|
| Proteostasis | 1 | 2023 | 36 | 0.200 |
Why?
|
| Gene Silencing | 5 | 2013 | 230 | 0.200 |
Why?
|
| Endoribonucleases | 1 | 2023 | 86 | 0.190 |
Why?
|
| Immunization | 3 | 2011 | 307 | 0.190 |
Why?
|
| Vasomotor System | 4 | 2009 | 19 | 0.190 |
Why?
|
| Vaccines, Synthetic | 3 | 2016 | 321 | 0.190 |
Why?
|
| Arteriosclerosis | 5 | 2005 | 110 | 0.190 |
Why?
|
| Lactic Acid | 2 | 2016 | 144 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 174 | 0.190 |
Why?
|
| Capillary Permeability | 3 | 2013 | 72 | 0.180 |
Why?
|
| Immunity, Mucosal | 1 | 2002 | 90 | 0.180 |
Why?
|
| Coronary Artery Disease | 5 | 2007 | 865 | 0.180 |
Why?
|
| Stem Cells | 4 | 2011 | 712 | 0.180 |
Why?
|
| Models, Biological | 5 | 2010 | 1392 | 0.180 |
Why?
|
| Curcumin | 4 | 2005 | 43 | 0.180 |
Why?
|
| Gene Expression Regulation | 8 | 2013 | 2356 | 0.180 |
Why?
|
| Lysophosphatidylcholines | 3 | 2005 | 13 | 0.180 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2013 | 98 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2022 | 86 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 667 | 0.170 |
Why?
|
| Masoprocol | 2 | 2011 | 7 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 2648 | 0.170 |
Why?
|
| Cell-Free System | 4 | 2013 | 62 | 0.170 |
Why?
|
| Cholangiocarcinoma | 2 | 2013 | 126 | 0.170 |
Why?
|
| Oncogenes | 2 | 2013 | 164 | 0.170 |
Why?
|
| Pancreatitis | 2 | 2020 | 140 | 0.170 |
Why?
|
| Tissue Engineering | 6 | 2010 | 168 | 0.170 |
Why?
|
| Tunica Intima | 3 | 2006 | 61 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2009 | 260 | 0.170 |
Why?
|
| Antibodies, Viral | 2 | 2009 | 1169 | 0.170 |
Why?
|
| Heparin | 3 | 2009 | 206 | 0.170 |
Why?
|
| Cholesterol | 3 | 2009 | 541 | 0.160 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 188 | 0.160 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2019 | 105 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 5 | 2012 | 204 | 0.160 |
Why?
|
| S Phase | 2 | 2011 | 73 | 0.160 |
Why?
|
| Transfection | 5 | 2016 | 960 | 0.160 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2011 | 74 | 0.160 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 713 | 0.160 |
Why?
|
| Lactosylceramides | 2 | 2009 | 7 | 0.150 |
Why?
|
| Immunologic Memory | 1 | 2021 | 202 | 0.150 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2008 | 34 | 0.150 |
Why?
|
| Cetuximab | 1 | 2019 | 13 | 0.150 |
Why?
|
| Up-Regulation | 6 | 2019 | 832 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2013 | 376 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 6 | 2009 | 1488 | 0.150 |
Why?
|
| Antibodies | 3 | 2011 | 357 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2013 | 1521 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2019 | 65 | 0.150 |
Why?
|
| Cell Division | 8 | 2011 | 730 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 600 | 0.140 |
Why?
|
| Sus scrofa | 5 | 2011 | 115 | 0.140 |
Why?
|
| Base Sequence | 5 | 2011 | 2782 | 0.140 |
Why?
|
| Selenomethionine | 4 | 2012 | 8 | 0.140 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 77 | 0.140 |
Why?
|
| Tyrphostins | 2 | 2008 | 13 | 0.140 |
Why?
|
| Thrombosis | 2 | 2022 | 495 | 0.140 |
Why?
|
| Chlamydophila pneumoniae | 2 | 2009 | 10 | 0.140 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 211 | 0.140 |
Why?
|
| Pyridones | 1 | 2019 | 148 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 1217 | 0.140 |
Why?
|
| Interleukin-10 | 2 | 2011 | 185 | 0.130 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2007 | 472 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 501 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2019 | 296 | 0.130 |
Why?
|
| Arteries | 6 | 2009 | 210 | 0.130 |
Why?
|
| Administration, Intranasal | 3 | 2015 | 130 | 0.130 |
Why?
|
| Nitric Oxide | 9 | 2014 | 466 | 0.130 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2016 | 20 | 0.130 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2016 | 2 | 0.130 |
Why?
|
| Polyethyleneimine | 1 | 2016 | 10 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 358 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2010 | 23 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1258 | 0.120 |
Why?
|
| Allopurinol | 2 | 2016 | 79 | 0.120 |
Why?
|
| Nucleic Acids | 1 | 2016 | 26 | 0.120 |
Why?
|
| Inflammation | 4 | 2009 | 1492 | 0.120 |
Why?
|
| Peroxynitrous Acid | 1 | 2016 | 8 | 0.120 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 76 | 0.120 |
Why?
|
| Polytetrafluoroethylene | 3 | 2007 | 62 | 0.120 |
Why?
|
| Th2 Cells | 2 | 2007 | 186 | 0.120 |
Why?
|
| Antigen Presentation | 2 | 2007 | 118 | 0.120 |
Why?
|
| Vitamin E | 1 | 2016 | 63 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 2016 | 71 | 0.120 |
Why?
|
| Plant Preparations | 2 | 2006 | 15 | 0.120 |
Why?
|
| Zonula Occludens-1 Protein | 3 | 2013 | 17 | 0.120 |
Why?
|
| Tumor Burden | 2 | 2013 | 239 | 0.120 |
Why?
|
| Hormones, Ectopic | 2 | 2005 | 7 | 0.120 |
Why?
|
| Fasciola hepatica | 2 | 2013 | 6 | 0.120 |
Why?
|
| Thrombomodulin | 2 | 2005 | 18 | 0.110 |
Why?
|
| Nitriles | 1 | 2016 | 165 | 0.110 |
Why?
|
| Ginkgolides | 2 | 2012 | 7 | 0.110 |
Why?
|
| Forecasting | 2 | 2015 | 361 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 119 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2010 | 88 | 0.110 |
Why?
|
| Vaccinia virus | 2 | 2005 | 50 | 0.110 |
Why?
|
| Female | 14 | 2016 | 71145 | 0.110 |
Why?
|
| Lactones | 2 | 2012 | 44 | 0.110 |
Why?
|
| Germinal Center | 2 | 2016 | 37 | 0.110 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2004 | 31 | 0.110 |
Why?
|
| Stress, Mechanical | 4 | 2008 | 179 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2013 | 350 | 0.110 |
Why?
|
| Claudin-1 | 3 | 2009 | 19 | 0.100 |
Why?
|
| Neointima | 2 | 2011 | 46 | 0.100 |
Why?
|
| Adenosine Triphosphate | 3 | 2010 | 265 | 0.100 |
Why?
|
| Drug Administration Routes | 2 | 2015 | 33 | 0.100 |
Why?
|
| RNA | 4 | 2016 | 531 | 0.100 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Molybdenum | 1 | 2013 | 10 | 0.100 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2013 | 8 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2013 | 28 | 0.100 |
Why?
|
| RNA, Untranslated | 2 | 2011 | 106 | 0.100 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 16 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 85 | 0.100 |
Why?
|
| DNA Damage | 3 | 2012 | 527 | 0.100 |
Why?
|
| Organoselenium Compounds | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cyclin D1 | 2 | 2010 | 109 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1957 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2013 | 17 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2013 | 239 | 0.100 |
Why?
|
| Open Reading Frames | 1 | 2013 | 200 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2015 | 140 | 0.100 |
Why?
|
| Disease Progression | 3 | 2008 | 2206 | 0.100 |
Why?
|
| Neutralization Tests | 2 | 2004 | 226 | 0.100 |
Why?
|
| Receptors, IgG | 3 | 2010 | 59 | 0.100 |
Why?
|
| Vasoconstriction | 3 | 2008 | 95 | 0.100 |
Why?
|
| Uric Acid | 1 | 2013 | 110 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 3615 | 0.100 |
Why?
|
| HIV Protease | 1 | 2012 | 3 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 835 | 0.100 |
Why?
|
| Zinc | 1 | 2013 | 128 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2009 | 769 | 0.090 |
Why?
|
| Cadherins | 4 | 2006 | 178 | 0.090 |
Why?
|
| Salicylates | 1 | 2012 | 54 | 0.090 |
Why?
|
| Interleukin-4 | 2 | 2010 | 145 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 140 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2010 | 121 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 195 | 0.090 |
Why?
|
| Models, Animal | 7 | 2009 | 460 | 0.090 |
Why?
|
| Estradiol | 2 | 2005 | 481 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 2564 | 0.090 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 579 | 0.090 |
Why?
|
| Prognosis | 3 | 2013 | 4952 | 0.090 |
Why?
|
| Larrea | 1 | 2011 | 3 | 0.090 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 28 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2008 | 370 | 0.090 |
Why?
|
| Hydroxyl Radical | 1 | 2012 | 13 | 0.090 |
Why?
|
| Luciferases, Renilla | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cyclin A | 1 | 2011 | 17 | 0.090 |
Why?
|
| Aorta | 4 | 2008 | 529 | 0.090 |
Why?
|
| Chromones | 1 | 2011 | 26 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2011 | 18 | 0.090 |
Why?
|
| Anions | 2 | 2008 | 15 | 0.090 |
Why?
|
| Protein Binding | 2 | 2013 | 1711 | 0.090 |
Why?
|
| Benzyl Alcohols | 1 | 2011 | 15 | 0.090 |
Why?
|
| Coumarins | 1 | 2011 | 23 | 0.090 |
Why?
|
| Cell Lineage | 2 | 2011 | 349 | 0.090 |
Why?
|
| Probability | 3 | 2007 | 310 | 0.090 |
Why?
|
| Capillaries | 3 | 2006 | 67 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 57 | 0.090 |
Why?
|
| Cholesterol Esters | 2 | 2008 | 11 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2004 | 315 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2011 | 127 | 0.090 |
Why?
|
| Gene Products, gag | 2 | 2016 | 20 | 0.090 |
Why?
|
| Morpholines | 1 | 2011 | 68 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 676 | 0.090 |
Why?
|
| Blood Coagulation | 2 | 2009 | 123 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2013 | 709 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2011 | 104 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 380 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 703 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 372 | 0.080 |
Why?
|
| Lipoproteins, LDL | 2 | 2008 | 118 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 749 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2011 | 82 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2009 | 267 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2010 | 396 | 0.080 |
Why?
|
| Gold | 1 | 2011 | 55 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2010 | 60 | 0.080 |
Why?
|
| Estrogens | 1 | 2013 | 436 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 165 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2011 | 55 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2008 | 89 | 0.080 |
Why?
|
| Hyperplasia | 5 | 2011 | 189 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 3 | 2005 | 66 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 362 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 382 | 0.080 |
Why?
|
| Plasmids | 2 | 2016 | 455 | 0.080 |
Why?
|
| Carotid Sinus | 1 | 2010 | 5 | 0.080 |
Why?
|
| Pressoreceptors | 1 | 2010 | 9 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2010 | 48 | 0.080 |
Why?
|
| Chemokine CCL11 | 1 | 2009 | 12 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 723 | 0.080 |
Why?
|
| Genes, bcl-1 | 1 | 2009 | 4 | 0.080 |
Why?
|
| Norwalk virus | 1 | 2010 | 115 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2006 | 432 | 0.080 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 55 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2011 | 131 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 680 | 0.080 |
Why?
|
| Isoflavones | 1 | 2009 | 42 | 0.080 |
Why?
|
| Water-Electrolyte Balance | 1 | 2010 | 81 | 0.080 |
Why?
|
| Leukosialin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Blood Vessels | 2 | 2011 | 98 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2007 | 191 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 139 | 0.080 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2009 | 15 | 0.080 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 5 | 2009 | 33 | 0.080 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 15 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1322 | 0.070 |
Why?
|
| Iliac Artery | 2 | 2006 | 63 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2009 | 435 | 0.070 |
Why?
|
| CD5 Antigens | 1 | 2009 | 33 | 0.070 |
Why?
|
| Survival Rate | 2 | 2011 | 2151 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2009 | 55 | 0.070 |
Why?
|
| Capsaicin | 1 | 2009 | 19 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2009 | 84 | 0.070 |
Why?
|
| Teratogens | 1 | 2009 | 86 | 0.070 |
Why?
|
| Time Factors | 6 | 2010 | 6279 | 0.070 |
Why?
|
| Nitroprusside | 5 | 2009 | 36 | 0.070 |
Why?
|
| Kinetics | 2 | 2007 | 1101 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2009 | 61 | 0.070 |
Why?
|
| Tight Junctions | 2 | 2005 | 39 | 0.070 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2008 | 7 | 0.070 |
Why?
|
| RNA Stability | 1 | 2009 | 75 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2008 | 22 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 739 | 0.070 |
Why?
|
| Janus Kinases | 1 | 2008 | 33 | 0.070 |
Why?
|
| Ghrelin | 1 | 2008 | 58 | 0.070 |
Why?
|
| Adiponectin | 2 | 2006 | 124 | 0.070 |
Why?
|
| Copper | 1 | 2009 | 74 | 0.070 |
Why?
|
| Molecular Structure | 1 | 2009 | 318 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 213 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2009 | 226 | 0.070 |
Why?
|
| Cobalt | 1 | 2008 | 16 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 693 | 0.070 |
Why?
|
| Nifedipine | 1 | 2008 | 21 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 286 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 85 | 0.070 |
Why?
|
| Spleen | 1 | 2009 | 256 | 0.070 |
Why?
|
| Membrane Proteins | 4 | 2009 | 1613 | 0.070 |
Why?
|
| Oxygen | 2 | 2008 | 552 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 152 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 111 | 0.070 |
Why?
|
| Oligonucleotides | 1 | 2008 | 96 | 0.070 |
Why?
|
| Smad Proteins | 1 | 2008 | 45 | 0.070 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 15 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 2008 | 252 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2009 | 426 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 111 | 0.070 |
Why?
|
| Ceramides | 1 | 2007 | 46 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2008 | 126 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 23 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 105 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 36 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 83 | 0.070 |
Why?
|
| Cell Death | 3 | 2016 | 237 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 99 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 138 | 0.060 |
Why?
|
| Actins | 4 | 2013 | 317 | 0.060 |
Why?
|
| Biomarkers | 8 | 2011 | 3405 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2008 | 901 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 313 | 0.060 |
Why?
|
| Mannose-Binding Lectins | 1 | 2006 | 26 | 0.060 |
Why?
|
| Male | 14 | 2011 | 65228 | 0.060 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2006 | 39 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 7 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 2143 | 0.060 |
Why?
|
| Leukemia Virus, Murine | 1 | 2006 | 5 | 0.060 |
Why?
|
| Hemagglutinins, Viral | 1 | 2006 | 22 | 0.060 |
Why?
|
| CD40 Antigens | 1 | 2006 | 25 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 69 | 0.060 |
Why?
|
| Vasodilator Agents | 4 | 2010 | 201 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 343 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2006 | 37 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 67 | 0.060 |
Why?
|
| Angioplasty | 1 | 2006 | 66 | 0.060 |
Why?
|
| alpha-Defensins | 1 | 2006 | 6 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2004 | 3864 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 2006 | 50 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2006 | 96 | 0.060 |
Why?
|
| Chlamydia Infections | 1 | 2006 | 53 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2006 | 66 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 30 | 0.060 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 139 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 288 | 0.060 |
Why?
|
| Hypoxia | 1 | 2007 | 245 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 37 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2006 | 123 | 0.060 |
Why?
|
| Particle Size | 2 | 2016 | 137 | 0.060 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 21 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 216 | 0.060 |
Why?
|
| Interleukin-17 | 1 | 2006 | 128 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2005 | 55 | 0.060 |
Why?
|
| Genomics | 1 | 2013 | 1624 | 0.060 |
Why?
|
| Receptors, Neuropeptide | 1 | 2005 | 11 | 0.060 |
Why?
|
| Baculoviridae | 1 | 2005 | 41 | 0.060 |
Why?
|
| Adenoviridae | 2 | 2005 | 582 | 0.060 |
Why?
|
| Methionine | 1 | 2005 | 96 | 0.060 |
Why?
|
| Defensins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Thymidine Kinase | 1 | 2005 | 89 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2011 | 44 | 0.060 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2004 | 6 | 0.050 |
Why?
|
| Panax | 1 | 2004 | 7 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 88 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 314 | 0.050 |
Why?
|
| CD4 Antigens | 1 | 2004 | 49 | 0.050 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2005 | 77 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 389 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2009 | 777 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 1833 | 0.050 |
Why?
|
| von Willebrand Factor | 4 | 2006 | 192 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 160 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 647 | 0.050 |
Why?
|
| Protein Folding | 1 | 2005 | 215 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 100 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2010 | 1344 | 0.050 |
Why?
|
| Comorbidity | 1 | 2009 | 1595 | 0.050 |
Why?
|
| Wine | 1 | 2003 | 15 | 0.050 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 121 | 0.050 |
Why?
|
| Leptin | 1 | 2005 | 219 | 0.050 |
Why?
|
| Gene Products, tat | 1 | 2003 | 27 | 0.050 |
Why?
|
| Mitochondria | 2 | 2009 | 759 | 0.050 |
Why?
|
| Plant Leaves | 1 | 2004 | 55 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 293 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2010 | 240 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2004 | 136 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 188 | 0.050 |
Why?
|
| Myography | 3 | 2009 | 8 | 0.050 |
Why?
|
| Compartment Syndromes | 1 | 2003 | 33 | 0.050 |
Why?
|
| Fascioliasis | 2 | 2013 | 6 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 2010 | 261 | 0.050 |
Why?
|
| Progesterone | 1 | 2005 | 446 | 0.050 |
Why?
|
| Mice, Inbred C3H | 3 | 2008 | 108 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 2 | 2004 | 539 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 200 | 0.050 |
Why?
|
| Neutrophils | 1 | 2005 | 372 | 0.050 |
Why?
|
| Biological Transport | 3 | 2008 | 333 | 0.050 |
Why?
|
| Leg | 1 | 2003 | 123 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 403 | 0.050 |
Why?
|
| Motor Activity | 1 | 2005 | 507 | 0.050 |
Why?
|
| Umbilical Veins | 3 | 2006 | 64 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 43 | 0.050 |
Why?
|
| Myositis | 1 | 2003 | 106 | 0.040 |
Why?
|
| Fibrin | 1 | 2022 | 64 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 3 | 2008 | 135 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2006 | 43 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 568 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2005 | 692 | 0.040 |
Why?
|
| Hypertension | 1 | 2010 | 1360 | 0.040 |
Why?
|
| Peptides | 1 | 2005 | 835 | 0.040 |
Why?
|
| Culture Techniques | 3 | 2007 | 75 | 0.040 |
Why?
|
| Luminescent Measurements | 3 | 2005 | 56 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2013 | 262 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 199 | 0.040 |
Why?
|
| Nanoparticles | 2 | 2016 | 292 | 0.040 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 82 | 0.040 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 455 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1021 | 0.040 |
Why?
|
| Ischemia | 1 | 2003 | 355 | 0.040 |
Why?
|
| Electromyography | 2 | 2011 | 141 | 0.040 |
Why?
|
| Catalase | 2 | 2010 | 64 | 0.040 |
Why?
|
| Mutation | 2 | 2011 | 6177 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2004 | 595 | 0.040 |
Why?
|
| Risk Factors | 5 | 2016 | 10959 | 0.040 |
Why?
|
| NADPH Oxidases | 2 | 2009 | 108 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 2 | 2009 | 73 | 0.040 |
Why?
|
| CD146 Antigen | 2 | 2011 | 6 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2012 | 442 | 0.040 |
Why?
|
| Caveolin 1 | 2 | 2009 | 51 | 0.040 |
Why?
|
| Nanotechnology | 2 | 2009 | 50 | 0.030 |
Why?
|
| Occludin | 2 | 2009 | 19 | 0.030 |
Why?
|
| Integrins | 2 | 2008 | 90 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 2 | 2008 | 62 | 0.030 |
Why?
|
| Critical Illness | 1 | 2022 | 615 | 0.030 |
Why?
|
| Tissue Culture Techniques | 2 | 2008 | 64 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 414 | 0.030 |
Why?
|
| Biocompatible Materials | 2 | 2009 | 122 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2008 | 18 | 0.030 |
Why?
|
| Shear Strength | 2 | 2008 | 15 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 955 | 0.030 |
Why?
|
| Febuxostat | 1 | 2016 | 21 | 0.030 |
Why?
|
| Iron Chelating Agents | 1 | 2016 | 14 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2006 | 24 | 0.030 |
Why?
|
| Cell Shape | 2 | 2006 | 70 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 1008 | 0.030 |
Why?
|
| E-Selectin | 2 | 2007 | 39 | 0.030 |
Why?
|
| Organ Culture Techniques | 2 | 2006 | 144 | 0.030 |
Why?
|
| Thy-1 Antigens | 1 | 2015 | 19 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2015 | 29 | 0.030 |
Why?
|
| Lipid A | 1 | 2015 | 23 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2008 | 361 | 0.030 |
Why?
|
| Wound Healing | 2 | 2009 | 476 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 117 | 0.030 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2005 | 4 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 486 | 0.030 |
Why?
|
| Perfusion | 2 | 2008 | 210 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 617 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2005 | 71 | 0.030 |
Why?
|
| Culture Media | 2 | 2005 | 175 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2006 | 277 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 2005 | 154 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 420 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 810 | 0.030 |
Why?
|
| Dogs | 2 | 2005 | 630 | 0.030 |
Why?
|
| Anastomosis, Surgical | 2 | 2004 | 175 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 233 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3834 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 517 | 0.020 |
Why?
|
| Heterografts | 1 | 2013 | 195 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2012 | 84 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3130 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 1617 | 0.020 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 20 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 83 | 0.020 |
Why?
|
| DNA | 1 | 2016 | 1442 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2011 | 93 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 155 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2010 | 25 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 47 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 123 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 60 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 358 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 198 | 0.020 |
Why?
|
| Equol | 1 | 2009 | 3 | 0.020 |
Why?
|
| Phytoestrogens | 1 | 2009 | 13 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 228 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 48 | 0.020 |
Why?
|
| Receptors, CCR3 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2010 | 115 | 0.020 |
Why?
|
| NADPH Oxidase 4 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 519 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2009 | 51 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2009 | 8 | 0.020 |
Why?
|
| Targeted Gene Repair | 1 | 2009 | 4 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 91 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 530 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2009 | 25 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 80 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 249 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2009 | 78 | 0.020 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2008 | 11 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 136 | 0.020 |
Why?
|
| Copper-transporting ATPases | 1 | 2009 | 27 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 241 | 0.020 |
Why?
|
| U937 Cells | 1 | 2008 | 23 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2010 | 334 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 33 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 37 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2011 | 231 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 14 | 0.020 |
Why?
|
| Carotid Artery Injuries | 1 | 2008 | 35 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 51 | 0.020 |
Why?
|
| NADP | 1 | 2008 | 54 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 256 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 387 | 0.020 |
Why?
|
| Incidence | 2 | 2007 | 3347 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 135 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2007 | 16 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1010 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2007 | 742 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2007 | 6 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2009 | 224 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2007 | 50 | 0.020 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 289 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2007 | 43 | 0.020 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2007 | 12 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 597 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 285 | 0.020 |
Why?
|
| Polyethylene Terephthalates | 1 | 2007 | 23 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 77 | 0.020 |
Why?
|
| Calcimycin | 1 | 2006 | 19 | 0.020 |
Why?
|
| Secretogranin II | 1 | 2006 | 1 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2006 | 50 | 0.020 |
Why?
|
| Plasma Substitutes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Dextrans | 1 | 2006 | 45 | 0.020 |
Why?
|
| Gene Products, env | 1 | 2006 | 16 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2006 | 74 | 0.020 |
Why?
|
| Trypsin | 1 | 2006 | 81 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2006 | 15 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2006 | 43 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 23 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 188 | 0.020 |
Why?
|
| Bioprosthesis | 1 | 2007 | 112 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 107 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 30 | 0.010 |
Why?
|
| Leukocytes | 1 | 2007 | 211 | 0.010 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 403 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2006 | 79 | 0.010 |
Why?
|
| Selenium Compounds | 1 | 2005 | 2 | 0.010 |
Why?
|
| Nelfinavir | 1 | 2005 | 4 | 0.010 |
Why?
|
| Indinavir | 1 | 2005 | 5 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 463 | 0.010 |
Why?
|
| Saquinavir | 1 | 2005 | 5 | 0.010 |
Why?
|
| Laminin | 1 | 2006 | 68 | 0.010 |
Why?
|
| Blood Cells | 1 | 2005 | 55 | 0.010 |
Why?
|
| Regeneration | 1 | 2008 | 231 | 0.010 |
Why?
|
| Hydrostatic Pressure | 1 | 2005 | 10 | 0.010 |
Why?
|
| Flavonoids | 1 | 2006 | 83 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2005 | 18 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 70 | 0.010 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 19 | 0.010 |
Why?
|
| Serotonin | 1 | 2006 | 212 | 0.010 |
Why?
|
| Vasculitis | 1 | 2005 | 47 | 0.010 |
Why?
|
| Furans | 1 | 2005 | 31 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 428 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2005 | 97 | 0.010 |
Why?
|
| Carbamates | 1 | 2005 | 66 | 0.010 |
Why?
|
| Integrin alpha4 | 1 | 2005 | 12 | 0.010 |
Why?
|
| Exonucleases | 1 | 2005 | 27 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2005 | 40 | 0.010 |
Why?
|
| Mesoderm | 1 | 2005 | 108 | 0.010 |
Why?
|
| Exoribonucleases | 1 | 2005 | 22 | 0.010 |
Why?
|
| Cell Count | 1 | 2005 | 217 | 0.010 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 17 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2005 | 73 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 2004 | 20 | 0.010 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2005 | 45 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 272 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 242 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2005 | 57 | 0.010 |
Why?
|
| Equipment Design | 1 | 2006 | 555 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 204 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2005 | 57 | 0.010 |
Why?
|
| Collagen | 1 | 2006 | 289 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2004 | 13 | 0.010 |
Why?
|
| Umbilical Cord | 1 | 2004 | 61 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2007 | 612 | 0.010 |
Why?
|
| Papio | 1 | 2004 | 58 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 228 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 810 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 272 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2655 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 224 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 301 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 200 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 14 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 19 | 0.010 |
Why?
|
| Pericardium | 1 | 2005 | 105 | 0.010 |
Why?
|
| Octreotide | 1 | 2003 | 24 | 0.010 |
Why?
|
| Software | 1 | 2009 | 752 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 322 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2006 | 404 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2004 | 97 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2005 | 579 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 429 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2004 | 181 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 200 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1397 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 172 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2004 | 182 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 187 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 302 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 296 | 0.010 |
Why?
|
| Aging | 1 | 2011 | 1264 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1418 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 171 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 464 | 0.010 |
Why?
|
| Ion Channels | 1 | 2004 | 206 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 423 | 0.010 |
Why?
|
| Stroke | 1 | 2011 | 1049 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 444 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 692 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 106 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 160 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2005 | 411 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2002 | 57 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1139 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1405 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 312 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 816 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 998 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2003 | 638 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1153 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2006 | 12964 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1990 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 1255 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1387 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1565 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1799 | 0.010 |
Why?
|
| Adult | 2 | 2010 | 31702 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 3094 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5296 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 5123 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3695 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 2436 | 0.010 |
Why?
|
| Middle Aged | 2 | 2004 | 28883 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 17666 | 0.000 |
Why?
|
| Aged | 1 | 2004 | 21255 | 0.000 |
Why?
|